Pancreatic Cancer and Immunotherapy: A Clinical Overview
Florentine E. F. Timmer(Amsterdam University Medical Centers), Tanja D. de Gruijl(Dutch Cancer Society), Hester J. Scheffer(Amsterdam UMC Location Vrije Universiteit Amsterdam), Sanne Nieuwenhuizen(Amsterdam University Medical Centers), Robbert S. Puijk(Amsterdam University Medical Centers), A. Bruynzeel(Vrije Universiteit Amsterdam), Madelon Dijkstra(Baptist Hospital of Miami), Evelien A. C. Schouten(Amsterdam University Medical Centers), Mirte Mayke Streppel(Johns Hopkins University), Jan J.J. de Vries(Amsterdam University Medical Centers), M. Petrousjka van den Tol(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bart Geboers(Amsterdam University Medical Centers), Johanna W. Wilmink, Martijn R. Meijerink(Amsterdam University Medical Centers)
Cited by 127
Related Papers
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597
Irreversible Electroporation for Nonthermal Tumor Ablation in the Clinical Setting: A Systematic Review of Safety and Efficacy
|Journal of Vascular and Interventional Radiology|2014|401